Medtronic (NYSE:MDT) Issues FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 5.600-5.660 for the period, compared to the consensus EPS estimate of 5.550. The company issued revenue guidance of $35.7 billion-$35.8 billion, compared to the consensus revenue estimate of $35.3 billion.

Medtronic Price Performance

Shares of NYSE:MDT opened at $92.74 on Tuesday. The business’s 50 day simple moving average is $89.43 and its 200-day simple moving average is $87.97. The firm has a market capitalization of $118.87 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 2.42 and a beta of 0.80. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.85 and a quick ratio of 1.42. Medtronic has a 12 month low of $79.29 and a 12 month high of $96.25.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.04. The company had revenue of $8.93 billion during the quarter, compared to the consensus estimate of $8.81 billion. Medtronic had a return on equity of 14.54% and a net margin of 13.90%. Medtronic’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.46 EPS. As a group, equities analysts forecast that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 26th. Medtronic’s dividend payout ratio is 78.45%.

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of recent research reports. Leerink Partnrs raised shares of Medtronic to a “strong-buy” rating in a report on Monday, June 16th. Leerink Partners started coverage on shares of Medtronic in a report on Monday, June 16th. They set an “outperform” rating and a $110.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $107.00 price objective (up previously from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Finally, Royal Bank Of Canada reduced their price objective on shares of Medtronic from $105.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, May 22nd. Twelve analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $98.19.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MDT. Evergreen Capital Management LLC increased its holdings in Medtronic by 5.8% during the second quarter. Evergreen Capital Management LLC now owns 15,034 shares of the medical technology company’s stock worth $1,321,000 after buying an additional 818 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Medtronic by 10.9% during the second quarter. CANADA LIFE ASSURANCE Co now owns 3,012,412 shares of the medical technology company’s stock worth $263,085,000 after purchasing an additional 295,768 shares during the period. 44 Wealth Management LLC boosted its position in Medtronic by 6.5% during the second quarter. 44 Wealth Management LLC now owns 50,607 shares of the medical technology company’s stock worth $4,411,000 after purchasing an additional 3,102 shares during the period. Tower Research Capital LLC TRC boosted its position in Medtronic by 20.7% during the second quarter. Tower Research Capital LLC TRC now owns 56,286 shares of the medical technology company’s stock worth $4,906,000 after purchasing an additional 9,665 shares during the period. Finally, MUFG Securities EMEA plc bought a new position in Medtronic during the second quarter worth about $330,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.